318 related articles for article (PubMed ID: 35909271)
21. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
22. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
23. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
24. Future potential targets of antibody-drug conjugates in breast cancer.
Corti C; Boscolo Bielo L; Schianca AC; Salimbeni BT; Criscitiello C; Curigliano G
Breast; 2023 Jun; 69():312-322. PubMed ID: 36996620
[TBL] [Abstract][Full Text] [Related]
25. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.
Antonarelli G; Corti C; Tarantino P; Salimbeni BT; Zagami P; Marra A; Trapani D; Tolaney S; Cortes J; Curigliano G
ESMO Open; 2023 Aug; 8(4):101608. PubMed ID: 37467660
[TBL] [Abstract][Full Text] [Related]
26. Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.
Yang T; Li W; Huang T; Zhou J
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569276
[TBL] [Abstract][Full Text] [Related]
27. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
28. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.
Ascione L; Crimini E; Trapani D; Marra A; Criscitiello C; Curigliano G
Oncologist; 2023 Nov; 28(11):944-960. PubMed ID: 37665782
[TBL] [Abstract][Full Text] [Related]
29. Lung toxicity induced by anti-HER2 antibody - drug conjugates for breast cancer.
Chai M; Li L; Wu H; Liu Y; Yi Z; Yu H
Crit Rev Oncol Hematol; 2024 Mar; 195():104274. PubMed ID: 38295890
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials.
Afzal F; Aiman W; Zahoor H; Bajwa AR; Kazmi SH; Anwar A; Anwar MY; Rashid S; Zubair H; Kashif T; Ashar Ali M
Breast Dis; 2023; 42(1):121-136. PubMed ID: 37125539
[TBL] [Abstract][Full Text] [Related]
31. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
Abelman RO; Medford A; Spring L; Bardia A
Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
[TBL] [Abstract][Full Text] [Related]
32. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
[TBL] [Abstract][Full Text] [Related]
33. [Expert consensus on the management of breast cancer antibody-drug conjugates infusion].
Breast Cancer Case Manager Branch of the Chinese Medical Education Association
Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(34):2704-2712. PubMed ID: 37675542
[TBL] [Abstract][Full Text] [Related]
34. Antibody drug conjugates for patients with breast cancer.
Medford A; Spring LM; Moy B; Bardia A
Curr Probl Cancer; 2021 Oct; 45(5):100795. PubMed ID: 34635342
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States.
Mudumba R; Chan HH; Cheng YY; Wang CC; Correia L; Ballreich J; Levy J
Value Health; 2024 Feb; 27(2):153-163. PubMed ID: 38042333
[TBL] [Abstract][Full Text] [Related]
36. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
37. The role of ado-trastuzumab emtansine in current clinical practice.
Turshudzhyan A
J Oncol Pharm Pract; 2021 Jan; 27(1):150-155. PubMed ID: 32838683
[TBL] [Abstract][Full Text] [Related]
38. HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Popović M; Silovski T; Križić M; Dedić Plavetić N
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175916
[TBL] [Abstract][Full Text] [Related]
39. [Not Available].
Mallet A; Ombline C; Robert M; Campone M; Frenel JS
Bull Cancer; 2021 Dec; 108(11S):11S19-11S25. PubMed ID: 34969512
[TBL] [Abstract][Full Text] [Related]
40. Antibody-Drug Conjugates in Triple Negative Breast Cancer.
Keskinkilic M; Sacks R
Clin Breast Cancer; 2024 Apr; 24(3):163-174. PubMed ID: 38341370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]